Globe Life (NYSE:GL - Get Free Report) issued its earnings results on Wednesday. The company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.12 by $0.02, Zacks reports. Globe Life had a net margin of 18.53% and a return on equity of 22.32%. Globe Life updated its FY 2025 guidance to 13.450-14.050 EPS.
Globe Life Stock Performance
NYSE:GL traded up $3.66 during mid-day trading on Friday, hitting $123.63. The company's stock had a trading volume of 958,110 shares, compared to its average volume of 510,240. The business's fifty day moving average is $113.19 and its two-hundred day moving average is $107.12. The stock has a market cap of $10.38 billion, a price-to-earnings ratio of 10.35 and a beta of 0.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.05 and a quick ratio of 0.05. Globe Life has a 1 year low of $38.95 and a 1 year high of $132.00.
Globe Life Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, January 6th were given a dividend of $0.24 per share. The ex-dividend date was Monday, January 6th. This represents a $0.96 dividend on an annualized basis and a yield of 0.78%. Globe Life's dividend payout ratio is presently 8.03%.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on GL. Truist Financial boosted their target price on Globe Life from $90.00 to $105.00 and gave the stock a "hold" rating in a research report on Friday, October 25th. BMO Capital Markets began coverage on shares of Globe Life in a report on Thursday, January 23rd. They issued a "market perform" rating and a $114.00 price target on the stock. Jefferies Financial Group boosted their price objective on Globe Life from $107.00 to $114.00 and gave the stock a "hold" rating in a research note on Tuesday, December 10th. Piper Sandler upped their target price on Globe Life from $118.00 to $130.00 and gave the company an "overweight" rating in a research note on Friday, October 25th. Finally, Raymond James increased their price objective on Globe Life from $160.00 to $188.00 and gave the stock a "strong-buy" rating in a research note on Tuesday, October 15th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $131.80.
View Our Latest Report on GL
Insider Activity
In related news, CMO Jennifer Allison Haworth sold 9,000 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $112.91, for a total transaction of $1,016,190.00. Following the completion of the sale, the chief marketing officer now owns 13,485 shares of the company's stock, valued at approximately $1,522,591.35. This represents a 40.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank M. Svoboda sold 13,448 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $112.56, for a total value of $1,513,706.88. Following the completion of the sale, the chief executive officer now directly owns 18,948 shares of the company's stock, valued at $2,132,786.88. This trade represents a 41.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,788 shares of company stock valued at $4,429,779 in the last quarter. 1.51% of the stock is currently owned by company insiders.
About Globe Life
(
Get Free Report)
Globe Life Inc, through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle- and middle-income families in the United States. The company operates in four segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments.
Read More
Before you consider Globe Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globe Life wasn't on the list.
While Globe Life currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
